Abbott India Ltd.

ABBOTINDIA

₹31775.0

0.67% (210.0)

Market Cap

₹66,951 Cr.

P/E

47.33

Key Ratios

Edit Ratio's

Market cap

66,951 Cr

47.33

Prom Holding

74.99 %

ROE (%)

32.48

ROCE (%)

42.51

Div Yield (%)

2.80

Sales

6,409 Cr

OPM (%)

26.44 %

Debt to Equity

Edit Ratio's

About

Abbott India Limited, a subsidiary of Abbott Laboratories, is a leading pharmaceutical company… Read more

Low

25325

52W Range

High

32200

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statementNew

Edit rows

Forensics

12 Yes

Positive for this company

2 Neutral

Neutral for this company

3 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Depreciation Effect

Depreciation accounting is not leading to increase in profits
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Retail Holding

Retail has been selling the stock which is usually a good time to buy
Revenue Recognition

Company is converting accounting profit to cash
Promoter Holding

Promoter has not sold any shares in the last 90 days

Price & Performance

Capex vs ROCE

Roce of the company has increased over the last three years
ROE

Net profit margin is responsible for roe increase over last 10 years
Share price

Share price has increased over last 10 years due to earnings
Working Capital

Working capital of the company seems to be under control
Debt

Company should not have issues servicing its debt
ROCE Strength

Roce of the company is consistently strong
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Current vs Historic Valuation

Company is trading at a premium to 3yr historic valuations
Sales Growth

Sales of the company has grown at a slow pace
Margin Stability

Margins of the company are volatile

Market Share

0 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

0.67 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

0.02 %

(as of Nov 20)

Historic

Antineo Plastic - Market Share

1.96 %

(as of May 19)

Historic

Blood Related - Market Share

0.32 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

32.40 %

(as of Mar 19)

Source/Historic

Creon - Market Share

0.61 %

(as of Nov 21)

Historic

Dermatology - Market Share

13.30 %

(as of Mar 19)

Source/Historic

Digene - Market Share

13.90 %

(as of Mar 19)

Source/Historic

Duphalac - Market Share

25.50 %

(as of Mar 19)

Source/Historic

Duphaston - Market Share

13.36 %

(as of Nov 21)

Historic

Endocrinology - Market Share

7.85 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

5.35 %

(as of Nov 21)

Historic

Gynecology - Market Share

63.40 %

(as of Mar 19)

Source/Historic

Influvac - Market Share

4.90 %

(as of Nov 21)

Historic

Neurological - Market Share

0.44 %

(as of Nov 21)

Historic

Pain - Market Share

6.20 %

(as of Dec 22)

Historic

Pharmaceutical Sector - Market Share

0.08 %

(as of Nov 21)

Historic

Respiratory - Market Share

0 %

(as of Jul 22)

Historic

Sex Stimulants - Market Share

0.02 %

(as of Apr 20)

Historic

Stomatological - Market Share

51.60 %

(as of Mar 19)

Source/Historic

Thyronorm - Market Share

16.70 %

(as of Mar 19)

Source/Historic

Udiliv - Market Share

1.81 %

(as of Jul 22)

Historic

Vaccines - Market Share

30.80 %

(as of Mar 19)

Source/Historic

Vertin - Market Share

4.51 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Acute vs Chronic

Dosage Form Break-Up

Brand Wise Break-Up

Operational Metrics

Domestic Sales Growth - YoY (%)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Brands

Brufen

Cremaffin Plus

Digene

Duphalac

Duphaston

Thyronorm

Zolfresh

Corporate Actions

Consolidated

DATE

DETAILS

Show Less

Suppliers

Suven Life Sciences Ltd.
Aarti Drugs Ltd.
TCPL Packaging Ltd.
TCI Express Ltd.
IOL Chemicals And Pharmaceuticals Ltd.
Snowman Logistics Ltd.
Prabhat Dairy Ltd.
Kilitch Drugs (India) Ltd.
Empire Industries Ltd.
Take Solutions Ltd.
Arshiya Ltd.

Showing 5 of 11

FAQs on Abbott India Ltd. Business

What does Abbott India do?

Abbott India Limited, a subsidiary of Abbott Laboratories, is a leading pharmaceutical company in India offering a wide range of high-quality medicines in various therapeutic categories with a focus on product development and clinical support.

Who are the competitors of Abbott India?

Abbott India major competitors are Aurobindo Pharma, Alkem Laboratories, Glaxosmithkline Phar, Glenmark Pharma, Lupin, Zydus Lifesciences, Mankind Pharma.
Market Cap of Abbott India is ₹66,951 Crs.
While the median market cap of its peers are ₹64,298 Crs.

Is Abbott India financially stable compared to its competitors?

Abbott India seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

View FAQ's On Shareprice

Cash Flow Machines

Actual Cash profits are more important than accounting profits. List of companies spitting out cash profits

Run Query

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release
Investor Presentation
Conference Call				Sep
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Abbott India Ltd.

View the discussion on ValuePickr

Pharmaceutical Sector

How The Pharma Industry Works - PPFAS

Deep Dive into Pharma Sector - Omkara Capital

Pharma Compliance In-Depth - Amit Rajan

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Nutraceuticals- Industry Overview - Value Educator

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Abbott India Ltd.

Abbott India Ltd.

Key Ratios

About

Timeline

Company Timeline

12 Yes

2 Neutral

3 No

0 No Data

Accounting & Shareholding

Contingent Liabilities

Depreciation Effect

Other Income

Pledge

Retail Holding

Revenue Recognition

Promoter Holding

Price & Performance

Capex vs ROCE

ROE

Share price

Working Capital

Debt

ROCE Strength

Balance Sheet Strength

Current vs Historic Valuation

Sales Growth

Margin Stability

Product Wise Break-Up

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Acute vs Chronic

UNLOCK PREMIUM

Dosage Form Break-Up

UNLOCK PREMIUM

Brand Wise Break-Up

UNLOCK PREMIUM

What does Abbott India do?

Who are the competitors of Abbott India?

Is Abbott India financially stable compared to its competitors?

SIGN UP FOR FREE